Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement

Taha Hatab, Syed Zaid, Priscilla Wessly, Nadeen Faza, Stephen H. Little, Marvin D. Atkins, Michael J. Reardon, Neal S. Kleiman, William A. Zoghbi, Sachin S. Goel

Structural Heart · 2023 · 10 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

Mitral transcatheter edge-to-edge repair (TEER) has proven to be a safe and effective treatment option in patients with primary mitral regurgitation (MR) at high or prohibitive surgical risk or those with secondary MR who remain symptomatic despite guideline-directed medical therapy (GDMT) and have favorable anatomy.1 Transcatheter mitral valve replacement (TMVR) is emerging as an important therapy for patients with symptomatic severe primary or secondary MR who are deemed high surgical risk and have unfavorable anatomy for TEER.

References

3